Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL. Srinagesh HK, Gupta V, Zhang A, Grunwald M, et al. Blood 2026;147:2011-2017.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Srinagesh HK, Gupta V, Zhang A, Grunwald M, et al. Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL. Blood 2026;147:2011-2017.
PMID: 41643192